natgillin/translations-raw huggingface dataset:
In clinical trials, no additional benefit was seen in the 600 mg group compared to the 300 mg group (see section 5.1).
V kliničnih raziskavah pri skupini bolnikov, ki so prejemali odmerek 600 mg, niso zaznali dodatne koristi v primerjavi s skupino bolnikov, kjer so bolniki prejemali odmerek 300 mg (glejte poglavje 5.1).
• add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see Section 5.1).
• kot dodatno zdravljenje velikih depresivnih epizod pri bolnikih z veliko depresivno motnjo (MDD - Major Depressive disorder ), ki so imeli suboptimalni odziv na antidepresivno monoterapijo (glejte poglavje 5.1).
• treatment of major depressive episodes in bipolar disorder.
• zdravljenje velikih depresivnih epizod pri bipolarni motnji;
Patients should be observed for signs and symptoms of infection and neutrophil counts followed (until they exceed 1.5 X 109/L).
Bolnike morate spremljati glede znakov in simptomov okužbe ter jim kontrolirati število nevtrofilcev (dokler ne preseže 1,5 x 109/l) (glejte poglavje 5.1).
There are no active controlled on long-term safety data in MDD and the placebo controlled randomised withdrawal data are of limited value due to decreased numbers of patients over time.
Za velike depresivne motnje ni aktivno nadzorovanih dolgoročnih varnostnih podatkov, s placebom nadzorovani naključni podatki o prenehanju jemanja zdravila pa imajo omejeno vrednost zaradi postopnega zmanjšanja števila bolnikov.
Elevations in prolactin1, increases in blood pressure2
zvišanje prolaktina1, zvišanje krvnega tlaka2
If you are pregnant, trying to get pregnant, or breast-feeding, talk to your doctor before taking Seroquel XR.
Če ste noseči, poskušate zanositi ali dojite, se pred jemanjem zdravila Seroquel SR posvetujte z zdravnikom.
Also caution should be exercised when quetiapine is prescribed either with medicines known to increase QT interval, or with concomitant neuroleptics, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia (see section 4.5).
Obenem je potrebna previdnost, če kvetiapin predpišete skupaj z zdravili, ki podaljšujejo interval QTc ali hkrati z drugimi nevroleptiki, zlasti pri starejših in pri bolnikih s prirojenim sindromom dolgega QT, kongestivnim srčnim popuščanjem, hipertrofijo srca, hipokaliemijo ali hipomagneziemijo (glejte poglavje 4.5).
The tablets should be swallowed whole and not split, chewed or crushed.
Bolnik mora tablete pogoltniti cele in jih ne sme lomiti, žvečiti ali drobiti.
In pre-clinical tests predictive of EPS, quetiapine is unlike typical antipsychotics and has an atypical profile.
V predkliničnih testih, ki napovedujejo EPU (ekstrapiramidne neželene učinke), se kvetiapin razlikuje od standardnih antipsihotikov in ima atipičen profil.
Very common (affects more than 1 in 10 people):
Zelo pogosti (pojavijo se pri več kot 1 od 10 oseb):
DE - Germany AstraZeneca GmbH, Tinsdaler Weg 183, 22880 Wedel,
AstraZeneca GmbH, Tinsdaler Weg 183, 22880 Wedel, Nemčija
Other than the incidence of extrapyramidal symptoms (see section 4.8 and ‘Clinical Safety' below) the tolerability of Seroquel XR once daily in elderly patients was comparable to that seen in adults (aged 18-65 years).
Razen incidence ekstrapiramidnih simptomov (glejte poglavje 4.8 in "Klinična varnost", spodaj) so starejši bolniki zdravilo Seroquel SR enkrat na dan prenašali podobno kot odrasli (stari od 18 do 65 let).
The frequencies of adverse events are ranked according to the following: Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000) and very rare
Pogostnosti neželenih dogodkov so razvrščene takole: zelo pogosti (> 1/10), pogosti (> 1/100, < 1/10), občasni (> 1/1000, < 1/100), redki (> 1/10.000, < 1/1000) in zelo redki (< 1/10.000).
Given the observed changes in weight, blood glucose (see hyperglycemia) and lipids seen in clinical studies, there may be possible worsening of the metabolic risk profile in individual patients, which should be managed as clinically appropriate (see also section 4.8).
Glede na opažene spremembe v telesni masi, nivoju glukoze v krvi (glejte poglavje hiperglikemija) in lipidih, ki so jih opažali v kliničnih raziskavah, lahko pride do poslabšanja profila metaboličnega tveganja pri posameznih bolnikih, kar je potrebno ustrezno klinično obravnavati (glejte poglavje 4.8).
Lipid changes should be managed as clinically appropriate.
Spremembe lipidov naj bodo ustrezno zdravljen.
In vitro CYP inhibition is observed only at concentrations approximately 5 to 50 fold higher than those observed at a dose range of 300 to 800 mg/day in humans.
In vitro je zavrtje CYP opazno le v koncentracijah, ki so približno 5- do 50-krat višje od koncentracij, ugotovljenih pri človeku med uporabo odmerkov v razponu od 300 do 800 mg/dan.
The elimination half lives of quetiapine and norquetiapine are approximately 7 and 12 hours, respectively.
Razpolovni čas izločanja kvetiapina je približno 7 ur, norkvetiapina pa približno 12 ur.
Longer term relapse prevention trials had an open label period (ranging from 4 to 36 weeks) during which patients were treated with quetiapine, followed by a randomized withdrawal period during which patients were randomized to quetiapine or placebo.
Dolgotrajnejša preskušanja za preprečevanje ponovitev so imela odprto obdobje (ki je segalo od 4 do 36 tednov); med odprtim obdobjem so bolniki prejemali kvetiapin, sledilo pa je randomizirano obdobje odtegnitve, med katerim so bolnike randomizirali na kvetiapin ali placebo.
The effect size of the 600 mg and 800 mg doses was greater than that of the 400 mg dose.
Učinek 600-mg in 800-mg odmerka je bil večji kot 400-mg odmerka.
Hypersensitivity to the active substance or to any of the excipients of this product.
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov v zdravilu.
The following studies were conducted with Seroquel XR as monotherapy treatment, however Seroquel XR is only indicated for use as add-on thereapy:
Naslednje študije so bile izvedene z zdravilom Seroquel SR kot monoterapijo, vendar je zdravilo Seroquel SR indicirano le za uporabo kot dodatno zdravilo:
The frequencies of adverse events are ranked according to the following: Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100, rare (≥1/10,000, <1/1000) and very rare (<1/10,000).
Pogostnosti neželenih dogodkov so razvrščene takole: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000) in zelo redki (< 1/10.000).
Bipolar depression patients and patients with major depressive episodes in MDD experiencing somnolence of severe intensity may require more frequent contact for a minimum of 2 weeks from onset of somnolence, or until symptoms improve and treatment discontinuation may need to be considered.
Bolniki z bipolarno depresijo in bolniki z velikimi depresivnimi epizodami pri veliki depresivni motnji, ki se jim pojavi huda zaspanost, lahko potrebujejo pogostejše stike vsaj 2 tedna od pojava zaspanosti, ali dokler se simptomi ne izboljšajo; včasih pride v poštev prekinitev zdravljenja.
As with other antipsychotics, caution should be exercised when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation.
Tako kot velja za druga antipsihotična zdravila, je tudi pri kvetiapinu potrebna pozornost pri bolnikih s srčno-žilnimi boleznimi ali družinsko anamnezo QT podaljšanja.
Furthermore, although lack of long-term efficacy data for add-on treatment was acknowledged, the CHMP agreed with extrapolation from the monotherapy relapse prevention study.
Kljub temu, da je bilo ugotovljeno pomanjkanje podatkov o dolgoročni učinkovitosti dodatnega zdravljenja, se je CHMP strinjal z ekstrapolacijo iz študije preprečevanja ponovnega pojava bolezni z monoterapijo.
Dizziness4, 17, somnolence 2, 17, headache
omotica4,17, zaspanost2,17, glavobol
In five placebo controlled monotherapy studies (including a study in elderly subjects) the effects of quetiapine in an unrestricted MDD population were shown.
V petih študijah monoterapije, nadzorovanih s placebom (vključno s študijo s starejšimi osebami), so bili prikazani učinki kvetiapina v neomejeni populaciji z velikimi depresivnimi motnjami.
(18) HDL cholesterol: <40 mg/dL (1.025 mmol/L) males; <50 mg/dL (1.282 mmol/L) females at any time.
(18) Holesterol HDL: < 40 mg/dl (1.025 mmol/l) moški; < 50 mg/dl (1.282 mmol/l) ženske kadarkoli
Women who are breastfeeding should therefore be advised to avoid breast-feeding while taking Seroquel XR.
Ženskam, ki dojijo, je zato treba svetovati, naj med uporabo zdravila Seroquel SR ne dojijo.
Elevations in gamma-GT levels3, Platelet count decreased14, QT prolongation 1,13, 19
zvišanje ravni gama-GT 3, zmanjšanje števila trombocitov14, podaljšanje intervala QT1,13,19
Tablet coating: hypromellose, macrogol, titanium dioxide (E171).
Obloga tablete: hipromeloza (E464), makrogol, titanov dioksid (E171).
Neuroleptic Malignant Syndrome:
Maligni nevroleptični sindrom:
An application for a type II variation to the terms of the Marketing Authorisation of Seroquel XR (NL/H/156/08-011/II/058) submitted by the marketing authorisation holder (MAH), Astra Zeneca AB, via Mutual Recognition Procedure (MRP) to include treatment of recurrent episodes in patients with Major Depressive Disorders (MDD), excluding the use as initial treatment and used when patients cannot be appropriately managed on alternative antidepressant treatment was rejected by all involved Member States on 15 May 2009.
Vlogo za spremembo tipa II dovoljenja za promet z zdravilom Seroquel XR (NL/H/156/08011/II/058), ki jo je vložil imetnik dovoljenja za promet z zdravilom (MAH) Astra Zeneca AB po postopku z medsebojnim priznavanjem, da bi se vključilo zdravljenje ponavljajočih epizod pri bolnikih z velikimi depresivnimi motnjami (MDD), izključilo uporabo kot začetno zdravljenje in dodalo uporabo, kadar bolnikov ni možno ustrezno zdraviti z alternativnimi antidepresivi, so 15. maja 2009 zavrnile vse udeležene države članice.
Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported rarely, including some fatal cases (see section 4.8).
Redko so poročali so o hiperglikemiji in/ali pojavu ali poslabšanju sladkorne bolezni, občasno s ketoacidozo ali komo, vključno z nekaj smrtnimi primeri (glejte poglavje 4.8).
The short-term monotherapy studies showed that patients treated with quetiapine had more adverse events and a higher dropout rate due to adverse events when compared to the active controlsSelective serotonin reuptake inhibitor - duloxetine and escitalopram.
Kratkoročne študije monoterapije so pokazale, da je bilo pri bolnikih, zdravljenih s kvetiapinom, več neželenih učinkov in večja stopnja osipa zaradi neželenih učinkov v primerjavi z aktivnima kontrolnima substancama - selektivnima zaviralcema ponovnega privzema serotonina - duloksetinom in escitalopramom.
- The CHMP further concluded that, although long-term safety data are lacking, the potential long-term safety concerns (in particular metabolic changes, EPS related events) including the potentially possible combinations of quetiapine as add-on treatment to be appropriately manage by collection of data in the already ongoing and new post authorisation safety studies which will be included in the updated Risk Management Plan.
- je CHMP zaključil, da je možno, čeprav podatki o dolgoročni učinkovitosti manjkajo, potencialne varnostne pomisleke (predvsem metabolne spremembe, neželene učinke, povezane z EPS), vključno z morebitnimi kombinacijami kvetiapina kot dodatnega zdravljenja, ustrezno obvladati z zbiranjem podatkov v tekočih in novih študijah o varnosti po odobritvi, ki bodo vključeni v posodobljen načrt za obvladovanje tveganja;
The number of patients with a mood event was 91 (22.5%) in the quetiapine group, 208 (51.5%) in the placebo group and 95 (26.1%) in the lithium treatment groups respectively.
Število bolnikov z epizodo motnje razpoloženja je bilo 91 (22,5%) v skupini bolnikov, ki je prejemala kvetiapin, 208 (51%) v skupini bolnikov, ki je prejemala placebo in 95 (26,1%) v skupini, ki je prejemala litij.
Seroquel XR should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension.
Zdravilo Seroquel SR je treba uporabljati previdno pri bolnikih s srčno-žilnimi boleznimi, možganskožilnimi boleznimi in drugimi stanji, ki povzročajo nagnjenost k hipotenziji.
Unknown:
Ni znano:
Based on shifts above clinically significant thresholds (adapted from the National Institutes of Health criteria) or increases >20mmHg for systolic or >10 mmHg for diastolic blood pressure at any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.
Na podlagi zgornjih sprememb klinično pomembni pragi (prirejeno po merilih National Institutes of Health) ali zvišanja sistoličnega tlaka > 20 mmHg ali diastoličnega tlaka > 10 mmHg kadarkoli v dveh akutnih (3- do 6-tedenskih) s placebom kontroliranih preskušanjih pri otrocih in mladostnikih.
- The CHMP considered whether it was appropriate to introduce Seroquel XR, at 50 - 300 mg/day to a population of patients with major depressive disorders, excluding the use as initial treatment and used when patients cannot be appropriately managed on alternative antidepressant treatment.
- je CHMP proučil, ali je primerno uporabiti zdravilo Seroquel XR v odmerku 50-300 mg/dan pri populaciji bolnikov z velikimi depresivnimi motnjami, brez uporabe kot začetno zdravljenje in vključno z uporabo, kadar bolnikov ni možno ustrezno zdraviti z alternativnim antidepresivnim zdravljenjem;
Like all medicines, Seroquel XR can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Seroquel SR neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
In a specific interaction study in psychotic patients, however, no increase in the cytochrome P450 activity was found after administration of quetiapine.
Toda v specifični študiji medsebojnega delovanja pri psihotičnih bolnikih po uporabi kvetiapina niso ugotovili povečanja aktivnosti citokroma P450.
Seroquel (quetiapine fumarate), prolonged release tablets (XR) at strength of 50 mg, 150 mg, 200 mg, 300 mg and 400 mg is authorised in the European Union via the Mutual Recognition and Decentralised procedures for the following indications:
Zdravilo Seroquel (kvetiapinijev fumarat), tablete s podaljšanim sproščanjem (XR) jakosti 50 mg, 150 mg, 200 mg, 300 mg in 400 mg, je v Evropski uniji odobren s postopki z medsebojnim priznavanjem in decentraliziranimi postopki za naslednje indikacije:
As with other antipsychotics and antidepressants, Seroquel XR should be used with caution in the elderly, especially during the initial dosing period.
Tako kot druga antipsihotična in antidepresivna zdravila se zdravilo Seroquel SR pri starejših bolnikih uporabljati previdno, še posebej v začetnem obdobju uporabe.
You, or someone in your family, have or have had any heart problems, for example heart rhythm problems or if you are taking any medicines that may have an impact on the way your heart beats.
Preden uporabite zdravilo, zdravniku povejte, če: če imate ali ste imeli vi ali kdo v vaši družini težave s srcem, na primer motnje srčnega ritma, ali če jemljete kakšna zdravila, ki lahko vplivajo na srčni utrip.
Quetiapine and several of its metabolites (including norquetiapine) were found to be weak inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro.
Za kvetiapin in več njegovih presnovkov (vključno z norkvetiapinom) je ugotovljeno, da in vitro rahlo zavirajo delovanje encimov 1A2, 2C9, 2C19, 2D6 in 3A4 humanega citokroma P450.
The following table summarises ADRs that occur in a higher frequency category in children and adolescents patients (10-17 years of age) than in the adult population or ADRs that have not been identified in the adult population.
Naslednja preglednica povzema neželene učinke zdravila, ki se pri otrocih in mladostnikih (starih od 10 do 17 let) pojavljajo v višji kategoriji pogostnosti kot v odrasli populaciji, ali neželene učinke zdravila, ki niso bili ugotovljeni v odrasli populaciji.
In post marketing, QT prolongation was reported with quetiapine at the therapeutic doses (see Section 4.8) and in overdose (see Section 4.9).
V obdobju po trženju so ugotovili podaljšanje QT pri terapevtskih odmekih (glejte poglavje 4.8) in pri prevelikem odmerjanju (glejte poglavje 4.9).
Clinical trials with Seroquel have shown that in addition to the known safety profile identified in adults (see section 4.8), certain adverse events occurred at a higher frequency in children and adolescents compared to adults (increased appetite, elevations in serum prolactin and extrapyramidal symptoms) and one was identified that has not been previously seen in adult studies (increases in blood pressure).
Klinična preskušanja zdravila Seroquel so pokazala, da so poleg znanih varnostnih značilnosti, ugotovljenih pri odraslih (glejte poglavje 4.8), nekateri neželeni učinki pri otrocih in mladostnikih pogostejši kot pri odraslih (večji apetit, zvišanje prolaktina v serumu in ekstrapiramidni simptomi), pojavil pa se je tudi neželen učinek, ki pred tem ni bil zabeležen v študijah pri odraslih (zvišan krvni tlak).
Renal impairment: Dosage adjustment is not necessary in patients with renal impairment.
Okvara ledvic: Pri bolnikih z okvaro ledvic odmerka ni treba prilagoditi.
The 50 mg, 200 mg and 300 mg tablets also contain iron oxide yellow (E172) and the 50 mg tablets contain iron oxide red (E172).
50-mg, 200-mg in 300-mg tablete vsebujejo tudi rumen železov oksid (E172) in 50 mg tablete vsebujejo rdeč železov oksid (E172).
During post-marketing experience, resolution of leucopenia and/or neutropenia has followed cessation of therapy with quetiapine.
Med obdobjem pomarketinške uporabe sta levkopenija in/ali nevtropenija po prenehanju zdravljenja s kvetiapinom izginili.
Seroquel XR 400 mg/day, 600 mg/day and 800 mg/day were associated with statistically significant improvements in psychotic symptoms compared to placebo.
Zdravilo Seroquel SR 400 mg/dan, 600 mg/dan in 800 mg/dan so psihotične simptome statistično značilno bolj izboljšali kot placebo.
Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with SEROQUEL XR and preventive measures undertaken.
Ker so pri bolnikih zdravljenih z antipsihotiki pogosto prisotni dejavniki tveganja za vensko tromboembolijo, je potrebno opredeliti vse dejavnike tveganja za vensko tromboembolijo pred in med zdravljenjem z zdravilom Seroquel SR, izvedejo pa naj se ustrezni preventivni ukrepi.
Given its primary central nervous system effects, quetiapine may interfere with activities requiring mental alertness.
Ker kvetiapin deluje v prvi vrsti na osrednje živčevje, lahko ovira dejavnosti, ki zahtevajo pozornost.
¾ General Practice Research Database (GPRD) Study;
¾ modificirano študijo spremljanja predpisovanja zdravila (M-PEM); ¾ študijo podatkovne zbirke raziskav splošne medicine (GPRD).
When adjusting for normal growth over longer term, an increase of at least 0.5 standard deviation from baseline in Body Mass Index (BMI) was used as a measure of a clinically significant change; 18.3% of patients who were treated with quetiapine for at least 26 weeks met this criterion.
V primeru korekcije za normalno rast v daljšem obdobju je bilo kot mera klinično pomembne spremembe uporabljeno povečanje za vsaj 0,5 standardnega odklona od izhodiščnega indeksa telesne mase (ITM); to merilo je izpolnilo 18,3 % bolnikov, ki so kvetiapin dobivali vsaj 26 tednov.
Doses greater than 300 mg should be initiated by physicians experienced in treating bipolar disorder.
Posameznim bolnikom lahko koristi odmerek 600 mg. Odmerke višje od 300 mg lahko uvede zdravnik, ki ima izkušnje z zdravljenjem bipolarne motnje.
AT - Austria AstraZeneca Österreich GmbH Schwarzenbergplatz 7 A-1037 Wien
AstraZeneca Österreich GmbH Schwarzenbergplatz 7
Skin and subcutaneous tissue disorders Very rare:
Bolezni kože in podkožja Zelo redki:
In elderly patients with major depressive episodes in MDD, dosing should begin with 50 mg/day on Days 1-3, increasing to 100 mg/day on Day 4 and 150 mg/day on Day 8.
Pri starejših bolnikih z velikimi depresivnimi epizodami, je treba odmerjanje začeti s 50 mg/dan od 1. do 3. dne, nato je treba odmerek povečati na 100 mg/dan 4. dan in na 150 mg/dan 8. dan.
Neuroleptic malignant syndrome has been associated with antipsychotic treatment, including quetiapine (see section 4.8).
Maligni nevroleptični sindrom je bil povezan z uporabo antipsihotičnih zdravil, vključno s kvetiapinom (glejte poglavje 4.8).
C/ Serrano Galvache, 56Edificio Roble 28033 Madrid Spain
C/ Serrano Galvache, 56 - Edificio Roble
The estimated risks of relapse after 6 months treatments was 14.3% for the Seroquel XR treatment group compared to 68.2% for placebo.
Ocenjeno tveganje recidiva po 6 mesecih zdravljenja je bilo 14,3 % v skupini, ki je dobivala zdravilo Seroquel SR, in 68,2 % v skupini, ki je dobivala placebo.
• treatment of bipolar disorder : o For the treatment of moderate to severe manic episodes in bipolar disorder o For the treatment of major depressive episodes in bipolar disorder o For the prevention of recurrence in patients with bipolar disorder, in patients whose manic or depressive episode has responded to quetiapine treatment .
• zdravljenje bipolarne motnje: o za zdravljenje zmernih do hudih maničnih epizod pri bipolarni motnji o za zdravljenje depresivnih epizod bipolarne motnje o za preprečevanje ponavljanja epizod pri bipolarni motnji, pri bolnikih, katerih manične ali depresivne epizode so bile odzivne na zdravljenje s kvetiapinom
IS - Iceland AstraZeneca A/S Roskildevej 22
AstraZeneca A/S Roskildevej 22
In addition, physicians should consider the potential risk of suicide-related events after abrupt cessation of quetiapine treatment, due to the known risk factors for the disease being treated.
Poleg tega morajo zdravniki zaradi znanih dejavnikov tveganja pri zdravljeni bolezni upoštevati možno tveganje s samomorom povezanih dogodkov po nenadni prekinitvi zdravljenja s kvetiapinom.
In nearly all cases, cessation of Seroquel treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment.
V skoraj vseh primerih je učinek na celotni in prosti T4 po prenehanju zdravljenja z zdravilom Seroquel izginil, ne glede na trajanje zdravljenja.
• Do not use Seroquel XR after the expiry date which is stated on the container after EXP.
• Zdravila Seroquel SR ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli za: »Uporabno do«.
WHAT SEROQUEL XR IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO SEROQUEL SR IN ZA KAJ GA UPORABLJAMO
Children and adolescents under 18 years Seroquel XR should not be used by children and adolescents aged under 18 years.
Otroci in mladostniki Zdravilo Seroquel SR se ne priporoča za bolnike mlajše od 18 let.
What Seroquel XR is and what it is used for Before you take Seroquel XR How to take Seroquel XR Possible side effects
Kaj je zdravilo Seroquel SR in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Seroquel SR Kako jemati zdravilo Seroquel SR Možni neželeni učinki
In general, reported signs and symptoms were those resulting from an exaggeration of the active substance's known pharmacological effects, ie, drowsiness and sedation, tachycardia and hypotension.
Na splošno so bili opisani znaki in simptomi posledica pretiranih znanih farmakoloških učinkov zdravila, tj. zaspanost in sedacija, tahikardija in hipotenzija.
• Increase in the amount of a hormone called prolactin, in the blood.
• Povečanje količine hormona prolaktina v krvi.